“We are looking forward to meeting with potential future partners at the JP Morgan’s Annual Healthcare Conference. The progress in our development programs of golexanolone in primary biliary cholangitis and hepatic encephalopathy has created a lot of interest before the meeting. Our newly communicated and intriguing data for golexanlone in Parkinson’s disease, and potentially also in other neurodegenerative diseases in the central nervous system that share similar underlying mechanisms, will also be discussed at the meeting,” says Anders Karlsson, CEO of Umecrine Cognition.

For further information, please contact:

Anders Karlsson, CEO, Umecrine Cognition AB
Phone: +46 70 – 918 00 10, e-mail: anders.karlsson@umecrine.se

About Umecrine Cognition AB

Umecrine Cognition AB develops a completely new class of pharmaceuticals against neurological disturbances in the brain that may arise as a consequence of several underlying diseases, leading to strongly reduced cognitive functions and wakefulness. Results from an internationally recognized clinical Phase 2 study indicates that the company’s most advanced drug candidate, golexanolone, normalizes the brain’s signaling and improves cognition as well as wakefulness in patients diagnosed with hepatic encephalopathy. The continued drug development will initially focus on patient groups whose symptoms arise from chronic liver diseases. The mode of action is however relevant in a number of other indications. For more information, visit www.umecrinecognition.com.